Omega Diagnostics Group (LON:ODX) Earns Corporate Rating from FinnCap

Omega Diagnostics Group (LON:ODX)‘s stock had its “corporate” rating reissued by research analysts at FinnCap in a report issued on Wednesday, May 22nd, ThisIsMoney.Co.Uk reports.

Shares of ODX remained flat at $GBX 10.25 ($0.13) during mid-day trading on Wednesday. The stock had a trading volume of 30,000 shares, compared to its average volume of 48,651. The stock has a market cap of $13.66 million and a P/E ratio of -1.97. The company has a current ratio of 1.82, a quick ratio of 1.18 and a debt-to-equity ratio of 3.80. Omega Diagnostics Group has a fifty-two week low of GBX 9.75 ($0.13) and a fifty-two week high of GBX 18 ($0.24).

About Omega Diagnostics Group

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases.

Read More: Analyzing a company’s cash flow statement

Receive News & Ratings for Omega Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.